A
PCVX icon

Abingworth’s Vaxcyte PCVX Stock Holding History

Abingworth’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$96.8M Sell
2,019,057
-2,149,661
-52% -$84.4M 31.54% 1
2022
Q3 		$100M Hold
4,168,718
– – 34.21% 1
2022
Q2 		$90.7M Hold
4,168,718
– – 29.04% 1
2022
Q1 		$101M Hold
4,168,718
– – 28.51% 1
2021
Q4 		$99.2M Hold
4,168,718
– – 24.03% 1
2021
Q3 		$106M Hold
4,168,718
– – 24% 1
2021
Q2 		$93.6M Hold
4,168,718
– – 28.94% 1
2021
Q1 		$82.1M Hold
4,168,718
– – 28.36% 1
2020
Q4 		$111M Hold
4,168,718
– – 37.88% 1
2020
Q3 		$206M Hold
4,168,718
– – 44.03% 1
2020
Q2 		$132M Buy
+4,168,718
New +$134M 36.77% 1

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return

Abingworth's PCVX Position: Q4 2022 in Review

Abingworth reduced its Vaxcyte (PCVX) stake by 52% in Q4 2022, selling an estimated $84.4M and leaving 2,019,057 shares worth $96.8M. The position accounts for 31.54% of the portfolio, ranked #1.

Abingworth first reported a position in PCVX in Q2 2020 and has held it in 11 quarters since. The position peaked at $206M in Q3 2020. 198 funds tracked by Wall St. Rank hold PCVX as of Q4 2022.

  • Abingworth held 2,019,057 shares of Vaxcyte worth $96.8M as of Q4 2022.
  • Abingworth sold 2,149,661 Vaxcyte shares in Q4 2022, an estimated $84.4M.
  • Vaxcyte made up 31.54% of Abingworth's portfolio in Q4 2022, its #1 holding.
  • Abingworth first reported a position in Vaxcyte in Q2 2020 and has held it in 11 quarters since.
  • Abingworth's Vaxcyte position peaked at $206M in Q3 2020.
  • 198 funds tracked by Wall St. Rank held Vaxcyte as of Q4 2022.

Based on Abingworth's 13F filing for Q4 2022, filed 10 Feb 2023.